Literature DB >> 26138172

Resolute zotarolimus eluting stent for treatment of long coronary lesions.

Martin Rothman1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26138172      PMCID： PMC4495596          DOI： 10.1016/j.ihj.2015.05.007

Source DB:  PubMed          Journal:  Indian Heart J        ISSN： 0019-4832


× No keyword cloud information.
  19 in total

1.  Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.

Authors:  Patrick W Serruys; Sigmund Silber; Scot Garg; Robert Jan van Geuns; Gert Richardt; Pawel E Buszman; Henning Kelbaek; Adrianus Johannes van Boven; Sjoerd H Hofma; Axel Linke; Volker Klauss; William Wijns; Carlos Macaya; Philippe Garot; Carlo DiMario; Ganesh Manoharan; Ran Kornowski; Thomas Ischinger; Antonio Bartorelli; Jacintha Ronden; Marco Bressers; Pierre Gobbens; Manuela Negoita; Frank van Leeuwen; Stephan Windecker
Journal:  N Engl J Med       Date:  2010-06-16       Impact factor: 91.245

2.  One-year outcomes of percutaneous coronary intervention with the 38-mm Resolute zotarolimus-eluting stent.

Authors:  Michael Lee; Shirish Hiremath; Robaayah Zambahari; Martin Leon; Laura Mauri; Alan Yeung
Journal:  Am J Cardiol       Date:  2013-08-14       Impact factor: 2.778

3.  One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry.

Authors:  Franz-Josef Neumann; Petr Widimsky; Jorge A Belardi
Journal:  EuroIntervention       Date:  2012-02       Impact factor: 6.534

4.  Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial.

Authors:  Alan C Yeung; Martin B Leon; Ash Jain; Thaddeus R Tolleson; Douglas J Spriggs; Brent T Mc Laurin; Jeffrey J Popma; Peter J Fitzgerald; Donald E Cutlip; Joseph M Massaro; Laura Mauri
Journal:  J Am Coll Cardiol       Date:  2011-04-04       Impact factor: 24.094

5.  Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year.

Authors:  Joshua M Stolker; David J Cohen; Kevin F Kennedy; Michael J Pencina; Jason B Lindsey; Laura Mauri; Donald E Cutlip; Neal S Kleiman
Journal:  Circ Cardiovasc Interv       Date:  2012-10-23       Impact factor: 6.546

6.  One-year outcomes from an all-comers chinese population of patients implanted with the resolute zotarolimus-eluting stent.

Authors:  Shubin Qiao; Lianglong Chen; Shaoliang Chen; Weimin Wang; Guoying Zhu
Journal:  Am J Cardiol       Date:  2013-11-23       Impact factor: 2.778

7.  Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.

Authors:  Riya Chacko; Meredith Mulhearn; Victor Novack; Lena Novack; Laura Mauri; Sidney A Cohen; Jeffrey Moses; Martin B Leon; Donald E Cutlip
Journal:  JACC Cardiovasc Interv       Date:  2009-06       Impact factor: 11.195

8.  Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions.

Authors:  Henning Kelbæk; Lene Holmvang; Gert Richardt; Franz R Eberli; Pieter Stella; Pawel E Buszman; Franz-Josef Neumann; Patrick W Serruys; Stephan Windecker; Petr Widimský; Jorge A Belardi; Sigmund Silber
Journal:  EuroIntervention       Date:  2015-10       Impact factor: 6.534

9.  Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial.

Authors:  Ian T Meredith; Stephen Worthley; Robert Whitbourn; Darren L Walters; Dougal McClean; Mark Horrigan; Jeffrey J Popma; Donald E Cutlip; Ann DePaoli; Manuela Negoita; Peter J Fitzgerald
Journal:  JACC Cardiovasc Interv       Date:  2009-10       Impact factor: 11.195

10.  Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program.

Authors:  Vasim Farooq; Pascal Vranckx; Laura Mauri; Donald E Cutlip; Jorge Belardi; Sigmund Silber; Petr Widimsky; Martin Leon; Stephan Windecker; Ian Meredith; Manuela Negoita; Frank van Leeuwen; Franz-Joseph Neumann; Alan C Yeung; Hector M Garcia-Garcia; Patrick W Serruys
Journal:  Heart       Date:  2013-03-06       Impact factor: 5.994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.